The FDA approved a label change for ferric carboxymaltose injection (Injectafer) to add a boxed warning for the risk of symptomatic hypophosphatemia. ^[1] A US district judge granted an FDA request to stay a hearing in a lawsuit filed by Florida and Texas, moving the hearing to December 1. ^[2] Researchers introduced FDARxBench, an expert-curated benchmark for evaluating document-grounded question-answering motivated by generic drug assessment. ^[3] An FDA Adverse Event Reporting System case series included reports of symptomatic hypophosphatemia that occurred after both single and multiple infusions of ferric carboxymaltose injection and resulted in hospitalizations. ^[4] Chronic hypophosphatemia associated with ferric carboxymaltose can also lead to osteomalacia (bone softening) and fractures. ^[5] Ferric carboxymaltose is an iron replacement therapy originally approved in 2013 for treating iron deficiency anemia in patients 1 year and older who cannot tolerate oral iron. ^[6] The delay is ostensibly to give more time for the government's internal review of the pill's safety data. ^[7] The lawsuit, brought by Florida and Texas, challenges the FDA's regulation of the abortion pill and its safety data. ^[8] Experiments across proprietary and open-weight models revealed substantial gaps in factual grounding, long-context retrieval, and safe refusal behavior. ^[9] The benchmark was constructed in collaboration with FDA regulatory assessors to ensure high-quality, expert-curated QA examples. ^[10] The new hearing date of December 1 is after the November midterm elections. ^[11]